CRISPR Therapeutics AG (CRSP)
50.76
+4.37
(+9.42%)
USD |
NASDAQ |
Nov 01, 16:00
50.80
+0.04
(+0.08%)
After-Hours: 20:00
CRISPR Therapeutics Total Liabilities (Quarterly): 358.90M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 358.90M |
March 31, 2024 | 355.08M |
December 31, 2023 | 346.77M |
September 30, 2023 | 359.04M |
June 30, 2023 | 380.99M |
March 31, 2023 | 389.47M |
December 31, 2022 | 367.58M |
September 30, 2022 | 399.40M |
June 30, 2022 | 372.53M |
March 31, 2022 | 361.26M |
December 31, 2021 | 352.42M |
September 30, 2021 | 308.80M |
June 30, 2021 | 295.72M |
March 31, 2021 | 152.41M |
December 31, 2020 | 163.73M |
September 30, 2020 | 141.72M |
June 30, 2020 | 135.86M |
Date | Value |
---|---|
March 31, 2020 | 121.20M |
December 31, 2019 | 127.33M |
September 30, 2019 | 128.71M |
June 30, 2019 | 126.56M |
March 31, 2019 | 118.06M |
December 31, 2018 | 96.82M |
September 30, 2018 | 101.59M |
June 30, 2018 | 87.98M |
March 31, 2018 | 84.12M |
December 31, 2017 | 83.51M |
September 30, 2017 | 103.36M |
June 30, 2017 | 107.17M |
March 31, 2017 | 107.17M |
December 31, 2016 | 112.12M |
September 30, 2016 | 341.18M |
June 30, 2016 | 157.72M |
December 31, 2015 | 188.55M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
121.20M
Minimum
Mar 2020
399.40M
Maximum
Sep 2022
288.96M
Average
352.42M
Median
Dec 2021
Total Liabilities (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 5.357B |
AC Immune SA | 126.94M |
Addex Therapeutics Ltd | 1.164M |
NLS Pharmaceutics Ltd | 10.46M |
Molecular Partners AG | 16.74M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 2.340B |
Shareholders Equity (Quarterly) | 1.981B |